A misconception needs to be cleared up!
- Thread starter JLM
- Start date
Actually some conditions like simple colds and flu's can lead to other issues that can cause even more problems down the road. A cold or flu can turn to a lung infection or bronchitis. Lung infections can cause scaring and lessions in the lungs which can turn cancerous. Bronchitis can affect the valves of your heart and cause heart issues.
Depending on the type of flu and it's implications (like H1N1) could be worse for the person who tries to let their body fight it.
Oddly enough Big Pharma can not back up any of their claims about flu vaccines with science either. What you call alternative medicine has been the way people were treated for thousands of years. Perhaps you are confusing medicine with faith healing. Like getting a shot of poison in the hopes it will prevent you from getting sick.
Check out post 17. "I guess the question is, were you serious or was it just another one of your troll threads?" - If this is polite I'd hate to see one of your cheeky ones!
WTF was talking to you? I was responding to Taxslave's intelligent post.
...according to prophesy
It was a serious question. You created the thread. Are you seriously interested in changing your behaviour or was the purpose of that thread to troll?
Well why don't you quit trolling then? No one that I know is seeking you out! Get used to it.
O.K. I just got the official word from Dr. Art Hister
Hi
Very briefly, 1) no one really knows when to update the old Pneumovax; some say 5 years, some say 10, some say it's good for much longer
I figure 10 year booster makes sense to me
2) since Pneumovax only covers some bacterial strains, it's still quite possible to come down with penumonia despite being vaccinated
3) to that end, there is now a 2nd vaccine approved in Canada for pneumonia although most doctors don't seem to be aware of it
here's the press release from Pfizer about that vaccine
Health Canada approves extended use of Prevnar® 13 in adults 50 years and older
Pfizer Canada Inc. is pleased to announce Health Canada's approval of the extended use of Prevnar® 13 for active immunization for the prevention of invasive pneumococcal disease (IPD) (including sepsis, meningitis, bacteraemic pneumonia, pleural empyema and bacteraemia) in adults 50 years of age and older caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.1 Prevnar® 13 is a conjugate vaccine made from the purified polysaccharides of 13 different serotypes of S. pneumoniae individually conjugated to non-toxic diphtheria cross reactive material 197 (CRM197) protein. Prevnar® 13 was first approved inDecember 2009 for use in children and infants from 6 weeks through 5 years of age for the active immunization against IPD caused by the serotypes of S. pneumoniae contained in the vaccine.
Older adults, and especially those with underlying medical conditions such as heart, liver or kidney disease, are at increased risk of invasive pneumococcal disease,2 which can result in a loss of quality of life.3
"Adults should be more proactive when it comes to vaccines, especially for those that protect against some serious infectious diseases," says Dr. Karl Weiss, Professor of Medicine, Maisonneuve-Rosemont Hospital, Faculty of Medicine, Université de Montréal. "In Canada, we recognize the importance of immunization for infants and children, but the benefits for adults are not widely discussed."
In addition to Canada, Prevnar® 13 is also approved for use in adults 50 years of age and older in the United States, European Union, Australia, Mexico and more than 10 other countries.
ABOUT INVASIVE PNEUMOCOCCAL DISEASE (IPD)
Pneumococcal disease is caused by the bacterium Streptococcus pneumoniae, also known aspneumococcus, which can infect people of all ages, although young children, older adults and individuals with certain chronic medical conditions are at an increased risk of infection. IPD occurs when bacteria invade parts of the body, such as the blood or spinal fluid, which are normally free from bacteria.
While less common than non-invasive pneumococcal disease, IPD is usually more severe, and it results in significant morbidity and mortality in older adults. It includes bacteraemic pneumonia (lung inflammation with bacteria in the blood), bacteraemia (bacteria in the blood) and meningitis (inflammation of the tissues surrounding the brain and spinal cord).
In Canada, the incidence of invasive pneumococcal disease in adults, especially the elderly, has remained high ranging from 23 per 100,000 to 29.4 per 100,000.4
Increased risk factors for invasive pneumococcal disease include older age, underlying chronic conditions, including chronic lung diseases, chronic heart disease, chronic liver disease and cirrhosis, diabetes, alcoholisim and cigarette use, immunosuppressive conditions including HIV infection, hematologic malignancies, generalized malignancies, solid organ and bone marrow transplant recipients, sickle cell disease, functional or anatomic asplenia and long-term use of systemic corticosteroids or immunosuppressive drugs.5
ABOUT PREVNAR® 13
Prevnar® 13 was first approved for use in infants and young children in December 2009 in Canadaand is now approved for such use in more than 100 countries worldwide. More than 400 million doses of Pfizer's pneumococcal conjugate vaccines for infants and children have been distributed worldwide, including approximately 9 million doses in Canada.
In clinical trials, Prevnar® 13 demonstrated a functional antibody response in adults 50 years of age and older who had not previously been vaccinated with a pneumococcal polysaccharide vaccine, and in those who had been previously vaccinated, including those with chronic, stable co-morbidities such as chronic cardiovascular disease, diabetes mellitus, and chronic pulmonary disease.6
The most commonly reported solicited local and systemic adverse events in clinical trials with Prevnar® 13 were redness, swelling and pain at the injection site, limitation of arm movement, decreased appetite, headache, diarrhea, chills, fatigue, rash and worsening of or new joint or muscle pain.
Prevnar® 13 is to be administered as a single dose of 0.5 mL to adults 50 years and older, including those previously vaccinated with a pneumococcal polysaccharide vaccine.7
Regardless of prior pneumococcal vaccination status, if sequential administration of Prevnar® 13 and pneumococcal polysaccharide vaccine is considered, Prevnar® 13 should be given first.8
ABOUT PFIZER CANADA INC.
Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical company. The company is one of the largest contributors to health research inCanada. Our diversified health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products.
Every day, Pfizer Canada employees work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We apply science and our global resources to improve the health and well being of Canadians at every stage of life.
Our commitment is reflected in everything Pfizer does, from our disease awareness initiatives to our community partnerships, to our belief that it takes more than medication to be truly healthy. To learn more about Pfizer's More than Medication philosophy and programs, visit morethanmedication.ca. To learn more about Pfizer Canada, visit www.pfizer.ca.
Best,
Art
www.drart.ca
Hi
Very briefly, 1) no one really knows when to update the old Pneumovax; some say 5 years, some say 10, some say it's good for much longer
I figure 10 year booster makes sense to me
2) since Pneumovax only covers some bacterial strains, it's still quite possible to come down with penumonia despite being vaccinated
3) to that end, there is now a 2nd vaccine approved in Canada for pneumonia although most doctors don't seem to be aware of it
here's the press release from Pfizer about that vaccine
Health Canada approves extended use of Prevnar® 13 in adults 50 years and older
Pfizer Canada Inc. is pleased to announce Health Canada's approval of the extended use of Prevnar® 13 for active immunization for the prevention of invasive pneumococcal disease (IPD) (including sepsis, meningitis, bacteraemic pneumonia, pleural empyema and bacteraemia) in adults 50 years of age and older caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.1 Prevnar® 13 is a conjugate vaccine made from the purified polysaccharides of 13 different serotypes of S. pneumoniae individually conjugated to non-toxic diphtheria cross reactive material 197 (CRM197) protein. Prevnar® 13 was first approved inDecember 2009 for use in children and infants from 6 weeks through 5 years of age for the active immunization against IPD caused by the serotypes of S. pneumoniae contained in the vaccine.
Older adults, and especially those with underlying medical conditions such as heart, liver or kidney disease, are at increased risk of invasive pneumococcal disease,2 which can result in a loss of quality of life.3
"Adults should be more proactive when it comes to vaccines, especially for those that protect against some serious infectious diseases," says Dr. Karl Weiss, Professor of Medicine, Maisonneuve-Rosemont Hospital, Faculty of Medicine, Université de Montréal. "In Canada, we recognize the importance of immunization for infants and children, but the benefits for adults are not widely discussed."
In addition to Canada, Prevnar® 13 is also approved for use in adults 50 years of age and older in the United States, European Union, Australia, Mexico and more than 10 other countries.
ABOUT INVASIVE PNEUMOCOCCAL DISEASE (IPD)
Pneumococcal disease is caused by the bacterium Streptococcus pneumoniae, also known aspneumococcus, which can infect people of all ages, although young children, older adults and individuals with certain chronic medical conditions are at an increased risk of infection. IPD occurs when bacteria invade parts of the body, such as the blood or spinal fluid, which are normally free from bacteria.
While less common than non-invasive pneumococcal disease, IPD is usually more severe, and it results in significant morbidity and mortality in older adults. It includes bacteraemic pneumonia (lung inflammation with bacteria in the blood), bacteraemia (bacteria in the blood) and meningitis (inflammation of the tissues surrounding the brain and spinal cord).
In Canada, the incidence of invasive pneumococcal disease in adults, especially the elderly, has remained high ranging from 23 per 100,000 to 29.4 per 100,000.4
Increased risk factors for invasive pneumococcal disease include older age, underlying chronic conditions, including chronic lung diseases, chronic heart disease, chronic liver disease and cirrhosis, diabetes, alcoholisim and cigarette use, immunosuppressive conditions including HIV infection, hematologic malignancies, generalized malignancies, solid organ and bone marrow transplant recipients, sickle cell disease, functional or anatomic asplenia and long-term use of systemic corticosteroids or immunosuppressive drugs.5
ABOUT PREVNAR® 13
Prevnar® 13 was first approved for use in infants and young children in December 2009 in Canadaand is now approved for such use in more than 100 countries worldwide. More than 400 million doses of Pfizer's pneumococcal conjugate vaccines for infants and children have been distributed worldwide, including approximately 9 million doses in Canada.
In clinical trials, Prevnar® 13 demonstrated a functional antibody response in adults 50 years of age and older who had not previously been vaccinated with a pneumococcal polysaccharide vaccine, and in those who had been previously vaccinated, including those with chronic, stable co-morbidities such as chronic cardiovascular disease, diabetes mellitus, and chronic pulmonary disease.6
The most commonly reported solicited local and systemic adverse events in clinical trials with Prevnar® 13 were redness, swelling and pain at the injection site, limitation of arm movement, decreased appetite, headache, diarrhea, chills, fatigue, rash and worsening of or new joint or muscle pain.
Prevnar® 13 is to be administered as a single dose of 0.5 mL to adults 50 years and older, including those previously vaccinated with a pneumococcal polysaccharide vaccine.7
Regardless of prior pneumococcal vaccination status, if sequential administration of Prevnar® 13 and pneumococcal polysaccharide vaccine is considered, Prevnar® 13 should be given first.8
ABOUT PFIZER CANADA INC.
Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical company. The company is one of the largest contributors to health research inCanada. Our diversified health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products.
Every day, Pfizer Canada employees work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We apply science and our global resources to improve the health and well being of Canadians at every stage of life.
Our commitment is reflected in everything Pfizer does, from our disease awareness initiatives to our community partnerships, to our belief that it takes more than medication to be truly healthy. To learn more about Pfizer's More than Medication philosophy and programs, visit morethanmedication.ca. To learn more about Pfizer Canada, visit www.pfizer.ca.
Best,
Art
www.drart.ca
Just got a little more information here, there's 3 basic causes of pneumonia, bacteria, virus and fungus. Pneumonia shots (so far) are mainly for the bacterial strain.
For matters medical, here's the website for the local authority
Got a question for Dr. Art Hister, contact him now.
The only thing I snort is rum.
Got a question for Dr. Art Hister, contact him now.
The only thing I snort is rum.
